Temozolomide Resistance in Glioblastoma by NRF2: Protecting the Evil

Temozolomide Resistance in Glioblastoma by NRF2: Protecting the Evil

The transcription factor NRF2 is constitutively active in glioblastoma, a highly aggressive brain tumor subtype with poor prognosis. Temozolomide (TMZ) is the primary chemotherapeutic agent for this type of tumor treatment, but resistance to this drug is often observed. This review highlights the re...

Full description

Bibliographic Details
Main Authors: Karoline Almeida Lima, Isabeli Yumi Araújo Osawa, Maria Carolina Clares Ramalho, Izadora de Souza, Camila Banca Guedes, Cláudio Henrique Dahne de Souza Filho, Linda Karolynne Seregni Monteiro, Marcela Teatin Latancia, Clarissa Ribeiro Reily Rocha
Format: Article
Language:English
Published: MDPI AG 2023-04-01
Series:Biomedicines
Subjects:
NRF2
glioblastoma
temozolomide
Online Access:https://www.mdpi.com/2227-9059/11/4/1081

Internet

https://www.mdpi.com/2227-9059/11/4/1081

Similar Items